News
The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...
The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
Panelist discusses how recent ASCO updates, particularly the SEQUOIA study results, highlight the long-term efficacy of zanubrutinib in high-risk patients and represent the most significant advances ...
Drs. Fatemeh Ardeshir-Larijani and Mohamed Abazeed discuss a validated AI model that can predict how patients with advanced ...
Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...
Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation of T cells. The growing prevalence of autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results